Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lumos Pharma Q1 2024 GAAP EPS $(1.29) Misses $(1.18) Estimate, Sales $165.00K Miss $302.60K Estimate

Author: Benzinga Newsdesk | May 14, 2024 04:53pm
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18) by 9.32 percent. The company reported quarterly sales of $165.00 thousand which missed the analyst consensus estimate of $302.60 thousand by 45.47 percent. This is a 76.12 percent decrease over sales of $691.00 thousand the same period last year.

Posted In: LUMO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist